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This study identified the barriers faced by people with bipolar affective disorder (BAD) regarding the need for
continuous medication. The qualitative approach was used, and the methodological framework was based on
the Grounded Theory in the light of Symbolic Interactionism. In total, of 14 people with BAD, who were being
attended at the Outpatient Unit for Mood Disorders of a university hospital, and 14 relatives indicated by them
participated in the study. The data collection was carried out through interviews and observation. Two categories
emerged from the results, describing the barriers faced by people with BAD: to have affective and cognitive
losses and to have several limitations. People with BAD feel ambivalent regarding medication adherence, as
they perceive that, no matter the direction they take, it will lead to a context of prejudice, losses and limitations
in various spheres of daily life.
DESCRIPTORS: bipolar disorder; self medication; interpersonal relations
TRASTORNO AFECTIVO BIPOLAR Y POR TERAPIA MEDICAMENTOSO:
IDENTIFICACIÓN DE BARRERAS
Este estudio identificó las barreras enfrentadas por las personas con Trastorno Afectivo Bipolar (TAB) ante la
necesidad del usar continuamente medicamentos. De enfoque cualitativo, tuvo como referencia metodológico,
a la Teoría Basada en los Datos, bajo la perspectiva de la Interacción Simbólica. Participaron del estudio 14
personas con TAB, las cuales seguían tratamiento en un servicio Ambulatorio para Trastornos del Humor de un
hospital universitario y 14 familiares señalados por los mismos. Las principales formas de obtención de datos
fueron la entrevista y la observación. Los resultados mostraron dos categorías que describen las barreras
enfrentadas por las personas con TAB: manifestar olvidos afectivos y cognoscitivos y la aparición de varias
limitaciones. Se constató que la persona con TAB sienten ambivalencia con relación al seguimiento
medicamentoso, pues perciben que cualquiera que sea la dirección adoptada, las conducirá al preconcepto,
pérdidas y limitaciones en las diversas esferas de su vida.
DESCRIPTORES: trastorno bipolar; automedicación; relaciones interpersonales
TRANSTORNO AFETIVO BIPOLAR E TERAPÊUTICA MEDICAMENTOSA:
IDENTIFICANDO BARREIRAS
Este estudo identificou as barreiras enfrentadas pela pessoa com Transtorno Afetivo Bipolar (TAB) frente à
necessidade de uso contínuo de medicamentos. Foi utilizada a abordagem qualitativa, tendo como referencial
metodológico a Teoria Fundamentada nos Dados, à luz do Interacionismo Simbólico. Participaram do estudo 14
pessoas com TAB que estavam em acompanhamento em um ambulatório de transtornos do humor de um
hospital universitário e 14 familiares indicados pelas mesmas. A entrevista e observação foram as principais
formas de obtenção de dados. Os resultados revelaram duas categorias que descrevem as barreiras enfrentadas
pela pessoa com TAB: ter perdas afetivas e cognitivas e ter várias limitações. Constatou-se que a pessoa com
TAB sente-se ambivalente em relação à adesão à terapêutica medicamentosa, pois percebem que, qualquer
que seja a direção adotada, ela o conduzirá a um contexto de preconceito, de perdas e limitações nas várias
esferas da vida cotidiana.
DESCRITORES: transtorno bipolar; automedicação; relações interpessoais
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INTRODUCTION
Around 450 million people suffer from mental
disorders, result of a complex interaction of genetic
and environmental factors(1). In this context, Bipolar
Affective Disorder (BAD) is considered a chronic
disorder, characterized by the existence of acute and
recurrent episodes of pathological change of mood.
Recovery after the acute phase is usually significant,
but less complete and free from consequences than
would be desirable(2). Considering the compromised
level, measured by several parameters, BAD is
responsible for 5 to 15% of new and longer psychiatric
hospitalizations, absorbing considerable health
system resources. It is also estimated that inadequate
treatment is responsible for the larger part of costs
deriving from the disorder.
Because BAD is a chronic disease, adherence
to the treatment is essential to increase chances of a
better prognosis. Efficacy is directly related to
adherence. The development of psychopharmacology
including the generalized use of antipsychotic,
antidepressant and anxiolytic medication(3) was
initiated in the 1950s. These medications represent,
since 1970, an economy of more than 40 billion dollars
in the United States; 13 billion in treatment costs and
27 billion in indirect costs. Without these modern
treatments, patients usually spent a quarter of their
adult life in hospital and half of it disabled(4).
However, there is a great and severe problem
in BAD treatment adherence, whose consequences
are lack of disorder control, increased avoidable
hospitalizations, and increased costs of healthcare.
Because of their magnitude, non-adherence and low
adherence to the therapy constitute a public health
problem. Literature has appointed some reasons for
non-adherence to medication treatment: patients do
not believe they are ill, do not see a reason to take
the medication; patients believe the medication will
hurt them; patients may be suffering from the
medication’s unpleasant side effects and believe it
causes more limitations than relief in their daily life,
among others(5).
This way, the proposal to study the medication
treatment issue among people with BAD meets the
increased interest in the issue and the need to optimize
treatment of this clientele. The importance of this
study is reinforced by epidemiological and
development aspects of BAD. Based on large
population studies, estimates of the prevalence of BAD
are around 1% for type I and II bipolar disorder.
Because of the introduction of the concept of bipolar
spectrum, enlarging the BAD threshold, estimates are
higher, around 5 to 8%. Affected individuals have
higher rates of unemployment and are subject to using
medical services and being hospitalized(6).
Because of scarce studies on medication
treatment adherence that focus on the phenomenon
in the patient, and the awareness that the use of
medication is a necessary reality in the daily routine
of people with BAD, we believe that a better
understanding of the associated and determinant
factors of this reality, from the perspective of those
who experience it, will allow for the testing of
interventions that optimize adherence and might
improve the control of the disorder and subsequent
re-hospitalizations. Additionally, a study of this nature
can contribute to discussions with the health team
involved in the treatment, aiming to improve the care
delivered to patients with BAD and their families.
OBJECTIVE
Identify, in the perspective of patient and
family, barriers faced by the person with BAD
regarding the need to continuously use the medication
required to control the disorder.
METODOLOGY
This study is part of a doctoral dissertation
entitled: “Between the devil and the deep blue sea:
the meaning of medication therapy for people with
bipolar affective disorder, according to their
perspectives and those of family members” defended
in 2006. After approval by the Research Ethics
Committee of the Hospital das Clinicas of the
University of Sao Paulo at Ribeirão Preto, Medical
School, the study was carried out in the households
of people with BAD, who were under treatment at the
Outpatient Unit of Mood Disorders (OCMD) of a large
university hospital in the interior of Sao Paulo, Brazil.
Because it is a qualitative study, the number
of participants with BAD and their respective family
members was not pre-defined, though it resulted in a
process of “theoretical sample”. Theoretical sample
means that the selection of participants is guided by
the emergent analysis. Thus, a selection criterion is
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that of theoretical relevance for the discovery and
development of the phenomenon under study(7).
Several techniques were used to determine
the patients and family members to be interviewed:
participant observation and informal interviews with
patients and family members, during the period in
which they were waiting to be attended at the OCMD;
verification of the patient’s file and inquiries among
physicians and nurses to obtain data regarding the
patients’ medication therapy. “Snowball” sampling was
also used. This method consists in the definition of a
sample through reference by people who share or
know others who have the characteristics of interest
for the study interest(8).
The study inclusion criteria of patients were:
having medical diagnosis of BAD; using psychotropic
medicament; being able to verbally express and
consent, in writing, the participation in the study. A
family member of each patient was also interviewed,
indicated as the more involved person or responsible
for the treatment, and who consented, in writing, to
participate in the study.
Taped interviews with 14 people with BAD,
and participant observation during household visits,
were used as the main strategies of data collection
between February 2005 and January 2006. The
interview was the basic source of data collection,
complemented by the researcher’s field notes taken
during visits to the outpatient clinic and to households.
The semi-structured interview was initiated with the
following question to the patient: “Tell me how it is
for you to use medication prescribed by the physician
of the psychiatric outpatient clinic”, and to the family
member: “Tell me how it is for your relative to use
the medication prescribed by the physician of the
psychiatric outpatient clinic”. The guiding questions
directed the points of the study to be explored. New
questions were added according to the participants’
answers and interview techniques were used to clarify
and support the experience (“could you tell me a little
bit more about it?”, “What is your idea in relation to
this matter?”, among others).
The data analysis was methodologically based
on the Grounded Theory (GT), in the light of Symbolic
Interactionism. Considering that the basic premise of
GD is constant comparison, the data collection and
analysis were carried out concomitantly. This way,
the first step of this analysis is the data transcription
per se, followed by the coding process. The coding
procedures are presented in three stages that
complete each other: open coding, axial coding and
selective coding(9).
The open coding is part of an analysis the
specifically serves to name phenomena through a
detailed exam of data, line by line(9-10). The mutual
comparison of codes gave rise to the categories, which
were integrated through axial coding. The identification
of categories allowed for the selective coding that
generated the central category “Between the devil
and the deep blue sea” in relation to the medication
therapy, revealing the ambiguity of the medicament
as a symbol. In this phase, all concepts and categories
were systematically related to the central category
and, from this point, their relations were analyzed.
We opt, in this article, to present barriers faced and
described by people with BAD in relation to the need
for the continuous use of medication to control the
disorder. The analysis process resulted in two
categories: to have affective and cognitive losses,
and several limitations. In order to preserve the
patients’ anonymity, we opt to identify them by the
letters of the alphabet. The family member of each
patient had an “F” added to the letter of the alphabet
assigned to him(er).
RESULTS
The participants’ reports revealed that the
disorder and its medication impose barriers to the
person with BAD as described in the following
categories.
To have affective and cognitive losses
To have affective losses
The patients’ emotional fragility due to the
disorder crises oftentimes results in affective
difficulties. They complain that, when they manage
to find a partner, the relationship suffers from
influences exerted by the partner’s family. The family
members’ reports confirm these influences. The
partner’s family deems that, because the patient is a
person with mental disorder, (s)he might not be able
to provide the care a family requires:
There were the affective losses also, the three boyfriends
I had, I lost them because of my disorder. He said his family sat
to talk and decided that I would not be a good partner for him…
would not be able to be a good mother, to take care of children in
a big city by myself. So, he thought I would not be self-sufficient
for that (G)
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It was really hard, my family put a lot of pressure for
me to separate. When people say the woman divorced the husband
because he is mentally ill I do not judge at all, I say: It is really
very difficult. We live together because we have a different
proposal in life (FH).
Sexual impotence, due to both symptoms
present in the depressive phase of the disorder as
side effects of the medication, can make marital
relationship even more difficult. This aspect is very
complex in men’s case because of the cultural factors
imposed on their sexual behavior. When the person
with BAD does not meet the sexual role idealized by
society, (s)he feels not only physically but also morally
impotent:
Up to a certain time, I was in a relationship with a
person, and it didn’t work, I’m with a problem of, how do you say?
Of libido, completely. It is difficult, I say like, how are you going
to have a relationship with a person and suddenly you don’t
answer, I wasn’t even having any erection anymore. It is
something that bothers; it is a huge emotional burden for me. (I)
Risperdal trashed me, left me completely unable to
have sexual relationships with my wife, I complete abstained for
a year and four months, completely crazy. (E)
In addition to affective losses, the person with
BAD also experiences cognitive losses, result of the
disorder symptoms and medication side effects.
To have cognitive losses
People with BAD evaluate their performance
in cognitive tasks as harmed by the medication
treatment. They complain of difficulties in
concentrating, even in pleasant activities, and lack of
memory, including in relation to tasks they perform
daily, such as reading, organizing personal belongings,
among others:
I can’t...forgetfulness... I can’t remember anything…
my memory is good-for-nothing… my mind doesn’t work… (I)
I started to lose organization in daily life. I started to
lose things, didn’t know where I put it, started to lose some
notions, I read it and couldn’t keep it and I’ve always liked reading
a lot, I’d see a movie and didn’t understand. (L)
The cognitive losses, such as difficulty in
memorizing, associated to other aspects inherent to
the development of the disorder, can become a source
of several limitations in daily life.
To have several limitations
To have limitations to study
Despite their desire to study, some people
with BAD do not manage to keep themselves in school,
usually because of the frequent and long periods of
absence due to crises and hospitalizations. Those who
have previous experiences with crises feel afraid of
making new attempts when they resume their studies.
Those who manage to study have to live with the
possibility of a crisis to occur in the classroom and,
when it occurs, they feel vulnerable to prejudice. Their
reports reveal frustrated attempts to resume studies:
I tried to study, it’s just that, I don’t know if it’s
because of the fear, I didn’t manage. In 81, I had a crisis because
I went to school and couldn’t study, I only finished sixth grade,
I wanted to finish because, then, I could have some direction in
life, but I couldn’t. (D)
It got in the way, because if you’re in the classroom,
and have a crisis and people have a prejudice against you… and
you need to take medication and cannot leave the classroom…
then the medication makes you sleepy, no teacher would
understand it. I used to go  to the Secretary of Education, so that
I wouldn’t lose the year, they don’t understand either… I lost
almost two years because of my problem. (K)
The limitations to study associated to the crisis
and the medication side effects can also result in
limitations at work.
To have limitations at work
The patients’ reports express their difficulty,
after manifestations of the disorder, in maintaining a
job or even finding a place in the job market. Factors
that may contribute to this limitation in the patients’
perspective include the disorder symptoms and the
perception, according to them, of the lack of emotional
structure to assume the responsibility any job
requires. They perceive themselves as not prepared
for work. Even when they manage to keep a job,
they frequently have their functional performance
harmed by the medication side effects, such as shaking
and sleepiness, among others. Their reports reveal
that the medication assumes a negative connotation
of something that limits their actions:
I haven’t worked for ten years. Since them, it wasn’t
lack of desire, it was a lack of condition, really, of structure… I got
a job, and had no conditions to face it. (E)
... there, at my job, it is very hectic and because of it,
sometimes I got blocked, the medication… the blurred vision,
shaking, all these got in the way, sure! (C)
It limited, because before I’d do a thousand things at
the same time and I managed. I can’t speed up too much or I’m
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going to blow a valve, the physical doesn’t react as it used to…I think
it is because of the drugs in the organism, the side effects. (F)
Because of the disorder crises and psychiatric
hospitalizations, it is not unusual for the person with
BAD to get health leaves and be dismissed when the
leave ends. The functional limitation as a consequence
of the medication side effects, including sleepiness,
is another factor of risk for discharge of these patients.
There are situations in which, despite their desire to
keep working, the patients do not manage to keep up
productivity at work, and retirement for disability is
necessary. If, for some, retirement represents a gain,
for others, it might represent a loss of financial
resources and autonomy, and also losses in social
relations and self-esteem. The reason is that, in
addition to the label of mental patient, with the
retirement, the person also gets the disability label
from society:
When my disease aggravated more and more,  my
employers didn’t want me anymore…there was a job in which I
got a health leave for a year…, then the day I went back, they
said: look, unfortunately there’s another person in your place. (D)
...the work, I retired, you know... because of dis-a-bi-
li-ty, I left the bank because of disability … I couldn’t manage to
work, how do you work? I took a lot of medication, sat on the
floor… then, they took me out. (N)
Limited capacity to work is generally
associated to financial limitations.
To have financial limitations
The financial limitation is also related to the
symptoms of the disorder, both in the maniac and
depressive phases. In the maniac phase, the
unjustified optimism, self confidence, grandiosity and
weak judgment lead the person with BAD to recklessly
get involved in pleasant activities, such as excessive
expenditures, debts, precipitated business, which can
produce destructive economic actions. In the
depression phase, on the other side, the person feels
exhausted, impotent and can get focused on his(er)
internal world. Due to his(er) anguish, (s)he can forget
to comply with commitments of several kinds,
including financial ones. Such attitudes, judged with
a low level of criticism during a maniac or depressive
episode, can cause harmful consequences:
I started to spend too much, to buy things without
being able to, you know? Compulsively. (E)
I lost a car because I didn’t pay it during the depression
phase. (L)
People with BAD who have their follow-up in the public
service generally receive medication prescriptions provided by
the Brazilian Single Health System (SUS). However, there are
times when these medications are not available in the health
services, or prescribed medications are not provided by the public
services. In these cases, patients need to buy them and, as they
generally use high doses, they perceive that this compromises
their family budget. This aspect is also evidenced in the family
members’ reports:
Of course, (it compromises the income), you see I take
280 pills of lithium per month.. (I)
She (patient) did not want to take depakene the doctor
prescribed because it was making her sick, then he (doctor)
prescribed valpakine. This is better, only that I have to buy it
and it is really difficult... (FB)
Limitations at work, with consequent financial
limitations, and the medication side effects can result
in the patients’ limited leisured time.
To have limited leisure
Sleepiness is a side effect mentioned by
patients with BAD that causes limitations in leisure
activities. As patients usually have to take medications
at night, they perceive themselves as not able to have
any nocturnal leisure activity. Also, diarrhea, when
present, makes the patient feel embarrassed to attend
public places, which in turn compromises his(er)
leisure. This context evidences that the person with
BAD, based on previous experiences, privileges
interaction with the medication to the detriment of
interaction with social objects in daily life, as the
reports of patients and family members reveal:
Diarrhea is bad because you cannot go out... my
schedule is taking medicine at 10pm, after 10 I don’t go anywhere.
It is a limitation… Will I take it and sleep on the street? Will I
sleep standing up? There is no way, so I have to take it and go to
bed.(D)
He played soccer, exercised, today he can’t anymore,
he barely walks, only the necessary inside the house. He says
it’s too tiresome (FH).
Another limitation mentioned by the person
with BAD, present in his(er) daily routine, refers to
the ability to drive vehicles.
To have limitations to drive vehicles
Despite their desire to conduct vehicles,
people with BAD do not have the courage to do it,
afraid that the medication side effects, such as
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sleepiness, diplopia, dizziness, among others, can
cause accidents. There are patients who want and
like to drive, but are influenced by other people,
including family, who deem that, due to the use of
psychotropic medication, they should not drive.
Although there are family members who deemed that
driving is allowed, which is not only a right of people
with BAD, but also a favorable aspect for their self-
esteem and autonomy, this was reduced many times,
due to the stigma and the disorder crises, as the
reports below reveal:
... I drive well, I like to drive, it’s something I do well,
there’re people who think that, because I take medication, I can’t
drive. (K)
... she can’t drive, and she wants to, because she’s
distracted, she doesn’t pay attention… and she wants to drive
again, we are scared to death. (FL)
So, why don’t you (physician) get him his driver’s
license? Only because he’s a psychiatric patient? Because if he
drives and gets independent, I mean, he’ll free me and he, his
self-esteem will get high… So, this would be very important for
him. (FH)
People with BAD express, in their reports,
that they live with many obstacles that need to be
overcome and resolved, so that quality of life can be
assured.
DISCUSSION
The experience of the disorder crises is
gradually accompanied by losses and limitations in
several spheres of daily life for the person with BAD(11).
The reports in this study evidenced affective and
cognitive losses, financial limitations, limitations at
work, among others. The data presented corroborate
with the literature, indicating that progressive losses
and limitations are associated, among other factors,
to the medication side effects and symptoms in
moments of crises. When in crisis, especially in the
maniac phase, patients can present aggressive
behaviors directed to family members and other
people in their social environment(12). Behaviors like
grandiosity, compulsive buying and psychomotor
agitation are also frequent in this phase of the disorder
and vulnerable to prejudice and rejection by the social
group(13), as evidenced in the reports of people with
BAD in this study.
Because the patient experiences intense
anguish when in the depression phase, (s)he has no
motivation to work, take care of oneself or keep up
ties(4). Therefore, almost always, psychiatric
hospitalizations are necessary in both phases of the
disorder, when symptoms are exacerbated.
Crises and hospitalization prevent the
permanence of the person with BAD in the work
environment, and cases of health leave with
subsequent discharge(14) are frequent. In this study,
patients expressed difficulties to keep their job or even
to get into the job market, after the manifestation of
the disorder, as a result of social prejudice or because
they felt incapable. As a consequence, they experience
financial and social losses and limitations. In the
literature on this topic, some studies corroborate with
these results(15-16). When they get unemployed, they
lose their acknowledged social roles and their self-
esteem, experiencing feelings of social exclusion and,
even when the benefits of social security alleviate
financial problems, they feel ashamed of having
income from public sources and unable to provide for
the family’s needs(16).
There is cognitive deterioration for some
people with affective disorder and studies that
evaluated performance in cognitive tasks showed,
among other aspects, deficiencies in attention and
memory tests(17). Regarding affective losses, the rate
of divorces is approximately two to three times higher
if compared to individuals considered “normal”(18).
Around 50% of all spouses report they would not have
married or had kids with the patients if they knew
they would have a mood disorder(19).
Because driving automotive vehicles requires
concentration, attention, fast reflexes, psychomotor
speed, capacity of decision, among other abilities,
mental disorders interfere in this activity in different
ways: through psychopathological symptoms, due to
the association with abuse and/or dependence of
substances and pharmacological treatment(20). Thus,
it is verified that the capacity to drive can be harmed
both in the presence of medicament adherence, due
its side effects, as in its absence, due to the
exacerbation of psychopathological symptoms,
corroborating with the results in this study.
FINAL CONSIDERATIONS
Reports showed that the fact they are people
with BAD or are treated with psychoactive medication
does not impede, but makes it difficult for them to
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remain in school, work, to form family units, and
participate in other social activities. In this
perspective, the ambivalence observed in relation to
the medicament therapy expresses their desire to
adhere to the medication or not. Patients perceive
that, whatever direction they adopt, it will lead them
to a context of prejudice, losses and limitations in
several areas of their daily life, both due to the side
effects of the medication, when they opt for
adherence, and due to the disorder crises and re-
hospitalizations, especially because of the lack of
medication.
Thus, the findings in this study entail direct
implications for care to the person with BAD in
medication treatment, allowing for the implementation
of actions according to their demands. Among these
strategies, we can suggest: adequate psycho-
educative process to patients and families, aiming to
improve their knowledge and sharing of experiences;
stimulate patients to question the several aspects of
the medication therapy, working as partners in the
treatment; and adopt the household visit, especially
for those people with BAD identified as at risk for
non-adherence to the medication therapy.
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